CJC-1295 needs a little more than its name
Before asking where it goes, there's a simpler question: which form are we talking about?
Those extra letters matter
CJC-1295 is a lab-made peptide designed to stimulate growth hormone release. That describes what it acts on. It doesn't establish a benefit you would notice in daily life.
Some preparations have an attachment called DAC. It binds to albumin, a common blood protein, and helps the substance last longer in circulation. The form called “without DAC” lacks that attachment.
FDA describes these as different active ingredients. They aren't interchangeable. The extra letters aren't fine print; they change what the name refers to. A useful comparison starts with the full name, before the route even enters the conversation.
The human study measured hormones
An early study in healthy adults found lasting rises in growth hormone and IGF-1, a related growth signal. The participants received injections under the skin.
That tells us something about hormone levels after those injections. It doesn't establish better sleep, stronger muscles or faster recovery. Those would be different outcomes, needing their own evidence.
FDA says the human studies appear to have used the DAC form, with the exact salt unspecified. Its review found no human studies of the form without DAC. There are limits here even before anyone tries to carry the result over to another route.
Lasting longer is different from getting in
A substance can stay in the blood for a long time once it arrives. That doesn't explain how it would get there from under the tongue.
The FDA review and human research discussed here don't supply that missing sublingual measurement. A long-lasting injection result can't fill it in.
This is the distinction I find easiest to lose in a promising description. “Lasts longer” sounds useful, but it answers a question about duration. “Gets through” is a separate question. The route comparison keeps the two apart.
What stays on the caution list
CJC-1295 has no FDA-approved medicine. In early injection studies, headaches, flushing and injection-site reactions were reported. Its long-term safety in people is unknown.
FDA also identifies serious reactions linked to CJC-1295, including a faster heart rate and reactions that widen blood vessels, with flushing or low blood pressure. A reported link doesn't by itself show how often a reaction will happen.
On FDA's page current as of April 22, 2026, CJC-1295 is listed as nominated but withdrawn. FDA still records safety concerns, including possible immune reactions. Withdrawal isn't approval or permission to compound, and the page gives no withdrawal date.
For a conversation about care, the useful pieces are the exact form, the proposed route and the human evidence that matches them.